Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134920666> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W3134920666 endingPage "250" @default.
- W3134920666 startingPage "249" @default.
- W3134920666 abstract "Abstract Aims We explored the ability of noninvasive tests (NITs) to identify patients (pts) with advanced fibrosis due to NASH. Methods All screened pts from the ongoing phase 3 REGENERATE with available histology data were included. Five NITs were evaluated using established literature cutoffs to identify or exclude advanced fibrosis (values between upper and lower thresholds were considered indeterminate): Aspartate Transaminase-to-Platelet Ratio Index (APRI; ≥0.57, ≤0.84), Enhanced Liver Fibrosis (ELF; ≥7.7, <9.8), Fibrosis-4 (FIB-4; ≥1.30, <2.67), NAFLD fibrosis score (NFS; ≥−1.455, <0.676), and Transient Elastography (TE; ≥7.9 kPa, <9.6 kPa). Three testing methods applied were single NIT, 2 simultaneous NITs weighted equally (NFS+ELF, FIB-4+ELF, NFS+TE, FIB-4+TE), and 2 sequential NITs with the second test performed only if the first test was indeterminate (NFS→ELF, FIB-4→ELF, NFS→TE, FIB-4→TE). Results 4133 pts in the REGENERATE screened population had an available biopsy (baseline liver biopsy: F0, 15.5%; F1, 27.2%; F2, 21.2%; F3, 29.6%; F4, 6.5%). Of these, 96% had FIB-4, NFS, and APRI, 41% had TE, and 28% had ELF. Single NITs with upper thresholds demonstrating strong specificity for identification of advanced fibrosis were FIB-4 (97%), NFS (94%), and APRI (86%); NITs with lower thresholds demonstrating good sensitivity for identification of early fibrosis were ELF (100%) and TE (88%). Evaluation of 2 simultaneous NITs resulted in a greater percentage of pts in the indeterminate zone. Application of 2 sequential tests improved the accuracy of identification and reduced misclassification vs 2 simultaneous tests. Conclusions Sequential NIT strategies may decrease liver biopsy rates while maintaining the accuracy of noninvasive diagnosis in pts with advanced fibrosis due to NASH. Funding Agencies Intercept Pharmaceuticals" @default.
- W3134920666 created "2021-03-15" @default.
- W3134920666 creator A5010123528 @default.
- W3134920666 creator A5014292494 @default.
- W3134920666 creator A5016102803 @default.
- W3134920666 creator A5018272606 @default.
- W3134920666 creator A5024034724 @default.
- W3134920666 creator A5024470010 @default.
- W3134920666 creator A5035862461 @default.
- W3134920666 creator A5036542143 @default.
- W3134920666 creator A5038609111 @default.
- W3134920666 creator A5043846829 @default.
- W3134920666 creator A5050215213 @default.
- W3134920666 creator A5052059601 @default.
- W3134920666 creator A5052875573 @default.
- W3134920666 creator A5064425382 @default.
- W3134920666 creator A5065731342 @default.
- W3134920666 creator A5071075621 @default.
- W3134920666 creator A5072395263 @default.
- W3134920666 creator A5080386622 @default.
- W3134920666 creator A5089357216 @default.
- W3134920666 creator A5091625375 @default.
- W3134920666 date "2021-03-01" @default.
- W3134920666 modified "2023-10-18" @default.
- W3134920666 title "A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL" @default.
- W3134920666 doi "https://doi.org/10.1093/jcag/gwab002.215" @default.
- W3134920666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7958710" @default.
- W3134920666 hasPublicationYear "2021" @default.
- W3134920666 type Work @default.
- W3134920666 sameAs 3134920666 @default.
- W3134920666 citedByCount "0" @default.
- W3134920666 crossrefType "journal-article" @default.
- W3134920666 hasAuthorship W3134920666A5010123528 @default.
- W3134920666 hasAuthorship W3134920666A5014292494 @default.
- W3134920666 hasAuthorship W3134920666A5016102803 @default.
- W3134920666 hasAuthorship W3134920666A5018272606 @default.
- W3134920666 hasAuthorship W3134920666A5024034724 @default.
- W3134920666 hasAuthorship W3134920666A5024470010 @default.
- W3134920666 hasAuthorship W3134920666A5035862461 @default.
- W3134920666 hasAuthorship W3134920666A5036542143 @default.
- W3134920666 hasAuthorship W3134920666A5038609111 @default.
- W3134920666 hasAuthorship W3134920666A5043846829 @default.
- W3134920666 hasAuthorship W3134920666A5050215213 @default.
- W3134920666 hasAuthorship W3134920666A5052059601 @default.
- W3134920666 hasAuthorship W3134920666A5052875573 @default.
- W3134920666 hasAuthorship W3134920666A5064425382 @default.
- W3134920666 hasAuthorship W3134920666A5065731342 @default.
- W3134920666 hasAuthorship W3134920666A5071075621 @default.
- W3134920666 hasAuthorship W3134920666A5072395263 @default.
- W3134920666 hasAuthorship W3134920666A5080386622 @default.
- W3134920666 hasAuthorship W3134920666A5089357216 @default.
- W3134920666 hasAuthorship W3134920666A5091625375 @default.
- W3134920666 hasBestOaLocation W31349206662 @default.
- W3134920666 hasConcept C126322002 @default.
- W3134920666 hasConcept C142724271 @default.
- W3134920666 hasConcept C202444582 @default.
- W3134920666 hasConcept C2775934546 @default.
- W3134920666 hasConcept C2777766500 @default.
- W3134920666 hasConcept C2780559512 @default.
- W3134920666 hasConcept C2908647359 @default.
- W3134920666 hasConcept C33923547 @default.
- W3134920666 hasConcept C71924100 @default.
- W3134920666 hasConcept C90924648 @default.
- W3134920666 hasConcept C94624232 @default.
- W3134920666 hasConcept C99454951 @default.
- W3134920666 hasConceptScore W3134920666C126322002 @default.
- W3134920666 hasConceptScore W3134920666C142724271 @default.
- W3134920666 hasConceptScore W3134920666C202444582 @default.
- W3134920666 hasConceptScore W3134920666C2775934546 @default.
- W3134920666 hasConceptScore W3134920666C2777766500 @default.
- W3134920666 hasConceptScore W3134920666C2780559512 @default.
- W3134920666 hasConceptScore W3134920666C2908647359 @default.
- W3134920666 hasConceptScore W3134920666C33923547 @default.
- W3134920666 hasConceptScore W3134920666C71924100 @default.
- W3134920666 hasConceptScore W3134920666C90924648 @default.
- W3134920666 hasConceptScore W3134920666C94624232 @default.
- W3134920666 hasConceptScore W3134920666C99454951 @default.
- W3134920666 hasIssue "Supplement_1" @default.
- W3134920666 hasLocation W31349206661 @default.
- W3134920666 hasLocation W31349206662 @default.
- W3134920666 hasOpenAccess W3134920666 @default.
- W3134920666 hasPrimaryLocation W31349206661 @default.
- W3134920666 hasRelatedWork W2008275663 @default.
- W3134920666 hasRelatedWork W2013716066 @default.
- W3134920666 hasRelatedWork W2033348731 @default.
- W3134920666 hasRelatedWork W2078815709 @default.
- W3134920666 hasRelatedWork W2104682956 @default.
- W3134920666 hasRelatedWork W2160029914 @default.
- W3134920666 hasRelatedWork W22195169 @default.
- W3134920666 hasRelatedWork W2418590106 @default.
- W3134920666 hasRelatedWork W2503956684 @default.
- W3134920666 hasRelatedWork W4238801417 @default.
- W3134920666 hasVolume "4" @default.
- W3134920666 isParatext "false" @default.
- W3134920666 isRetracted "false" @default.
- W3134920666 magId "3134920666" @default.
- W3134920666 workType "article" @default.